May 4, 2020 / 12:27 PM / 25 days ago

BRIEF-Lupin Announces Positive Topline Results From Study Of Single-Dose Solosec® For Treatment Of Trichomoniasis

May 4 (Reuters) - Lupin Ltd:

* LUPIN ANNOUNCES POSITIVE TOPLINE RESULTS FROM ITS PHASE 3 STUDY OF SINGLE-DOSE SOLOSEC® (SECNIDAZOLE) FOR THE TREATMENT OF TRICHOMONIASIS

* LUPIN PHARMACEUTICALS - PRIMARY ENDPOINT SUCCESSFULLY ACHIEVED IN PHASE 3 CLINICAL TRIAL OF SINGLE-DOSE SOLOSEC OF 147 PATIENTS

* LUPIN PHARMACEUTICALS - PLANS TO SUBMIT SUPPLEMENTAL NDA FOR SOLOSEC TO FDA FOR TREATMENT OF TRICHOMONIASIS IN H2 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below